Top in endocrinology: NASH epidemic, insulin and corticosteroids for COVID-19
Click Here to Manage Email Alerts
An upward trend in nonalcoholic steatohepatitis incidence prompted professional societies to call on clinicians to raise awareness and combine treatment strategies. It was the top story in endocrinology last week.
Another top story revealed that combining insulin with high doses of steroids may strip away the steroids’ pro-inflammatory effect. Researchers think that this could be helpful for patients hospitalized with COVID-19.
Photo source: Adobe Stock
Read these and more top stories in endocrinology below:
Experts issue ‘call to action’ to prepare for NASH epidemic
Eight professional societies issued a joint report on the dangers associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, calling on clinicians to work together across specialties and align treatment strategies. Read more.
Insulin, corticosteroids may produce additive anti-inflammatory effect in severe COVID-19
A combination of anti-inflammatory and antithrombotic actions induced by IV insulin infusion could provide “potent inhibition” of the effects of COVID-19 in hospitalized patients, according to a new review published in Diabetes Care. Read more.
Rare genetic variant may protect against obesity, provide new drug target
People with a rare genetic coding variant that occurs in approximately 1 in 3,000 people had lower BMI and 54% lower odds for obesity compared with those who were not heterozygous carriers, data published in Science show. Read more.
Curry, vitamin B2 intake may reduce risk for metabolic syndrome in women
Premenopausal women who eat more curry and postmenopausal women with a higher daily vitamin B2 intake are less likely to have metabolic syndrome, according to a study of women in Korea published in Menopause. Read more.
FDA approves first interchangeable biosimilar insulin
The FDA approved the first interchangeable biosimilar insulin product to improve glycemic control for children and adults with diabetes, part of an effort to provide cost-effective options, according to an agency press release. Read more.